Synmosa Biopharma Corporation
4114
Rank in Stocks
#12574
Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates... Synmosa Biopharma Corporation, established in Taipei, Taiwan, in 1980, operates as a dedicated specialty pharmaceutical enterprise. The company manages the entire lifecycle of pharmaceutical and healthcare products, from research and development to manufacturing, marketing, and distribution, primarily serving the Taiwanese market under its proprietary Synmosa brand. Its diverse product portfolio addresses key therapeutic categories, including cardiovascular health, respiratory conditions, urology, sex hormone treatments, and oncology. These offerings are available in various formats such as effervescent tablets, granules, nasal sprays, metered-dose inhalers, hormonal preparations, and other specialized forms. Beyond its proprietary products, Synmosa also extends its expertise through contract manufacturing services. The company maintains a significant international presence, exporting its goods to numerous countries including South Africa, China, Hong Kong, Thailand, Singapore, Malaysia, Vietnam, Myanmar, Cambodia, Peru, Costa Rica, and Nicaragua.
Share Price
$0.84746795
Last synced: 2026-11-10
Market Cap
$458.56M
Change (1 day)
-0.18%
Change (1 year)
-14.05%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Synmosa Biopharma Corporation (4114)
Category
Healthcare
Operating Margin for Synmosa Biopharma Corporation (4114)
Operating Margin as of November 2026 TTM: 10.70%
According to Synmosa Biopharma Corporation's latest financial reports, its current operating margin (TTM) is 10.70%. At the end of 2025 the company had an operating margin of 12.58%.
Operating Margin history for Synmosa Biopharma Corporation from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 10.70% | -14.94% |
| 2025 | 12.58% | -5.56% |
| 2024 | 13.32% | 11.37% |
| 2023 | 11.96% | -33.41% |
| 2022 | 17.96% | 179.75% |
| 2021 | 6.42% | -48.14% |
| 2020 | 12.38% | -411.06% |
| 2019 | -3.98% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -98.19% |
DE
|
|
| 19.68% | -98.16% |
DE
|
|
| 13.26% | -98.76% |
JP
|
|
| 17.08% | -98.40% |
CH
|
|
| 14.92% | -98.61% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Synmosa Biopharma Corporation's operating margin
What is Synmosa Biopharma Corporation's operating margin?
Synmosa Biopharma Corporation's operating margin is 10.70%, as of Nov 2026.
What was Synmosa Biopharma Corporation's operating margin in 2025?
In 2025, Synmosa Biopharma Corporation's operating margin was 12.58%, compared with 13.32% in 2024.
How has Synmosa Biopharma Corporation's operating margin changed since 2020?
From 2020 to 2025, Synmosa Biopharma Corporation's operating margin was highest in 2022 (17.96%) and lowest in 2021 (6.42%).
How does Synmosa Biopharma Corporation's operating margin compare with similar companies?
Synmosa Biopharma Corporation's operating margin (10.70%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.